Paclitaxel Treatment Options

A collection of 2051 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Home

All Treatments

Paclitaxel

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT06946797

Recruiting

The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/25/2025

Locations: Alaska Oncology and Hematology, Anchorage, Alaska +48 locations

Alaska Oncology and Hematology, Anchorage, Alaska

Local Institution - 0062, Los Angeles, California

Local Institution - 0063, Boise, Idaho

Local Institution - 0052, Boise, Idaho

Local Institution - 0064, Post Falls, Idaho

Local Institution - 0047, Cleveland, Ohio

Local Institution - 0033, Cleveland, Ohio

Local Institution - 0051, Allentown, Pennsylvania

Local Institution - 0041, Brasilia, Distrito Federal

Local Institution - 0043, Belo Horizonte, Minas Gerais

Local Institution - 0038, Porto Alegre, Rio Grande Do Sul

Local Institution - 0037, Barretos, São Paulo

Local Institution - 0034, São Paulo, Not set

Local Institution - 0068, Antofagasta, AN

Local Institution - 0067, Santiago, Región Metropolitana De Santiago

Local Institution - 0069, Viña del Mar, Valparaíso

Local Institution - 0065, Dijon, Côte-d'Or

Local Institution - 0003, Suresnes, Hauts-de-Seine

Local Institution - 0010, Paris, Île-de-France

Local Institution - 0012, Athens, Attikí

Local Institution - 0013, Chaidari, Attikí

Local Institution - 0011, Thessaloniki, Kentrikí Makedonía

Local Institution - 0014, Larissa, Thessalía

Local Institution - 0015, Meldola, Emilia-Romagna

Local Institution - 0057, Udine, Friuli-Venezia Giulia

Local Institution - 0020, Bergamo, Lombardia

Local Institution - 0019, Firenze, Toscana

Local Institution - 0017, Novara, Not set

Local Institution - 0025, Guadalajara, Jalisco

Local Institution - 0058, Monterrey, Nuevo León

Local Institution - 0027, Merida, Yucatán

Local Institution - 0024, Mexico, Not set

Local Institution - 0022, Puebla, Not set

Local Institution - 0081, Warszawa, Mazowieckie

Local Institution - 0080, Prabuty, Pomorskie

Local Institution - 0079, Łódź, Łódzkie

Local Institution - 0073, Bucharest, București

Local Institution - 0076, Florești, Cluj

Local Institution - 0077, Craiova, Dolj

Local Institution - 0075, Bucharest, Not set

Local Institution - 0074, Cluj, Not set

Local Institution - 0078, Iași, Not set

Local Institution - 0066, Pretoria, Gauteng

Local Institution - 0031, Soweto, Gauteng

Local Institution - 0009, Sandton, GP

Local Institution - 0084, Rondebosch, Western Cape

Local Institution - 0070, Adana, Not set

Local Institution - 0072, Ankara, Not set

Local Institution - 0071, Istanbul, Not set

Conditions: Non-Small Cell Lung Cancer

Learn More ›

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

NCT04329065

Recruiting

This phase II trial studies the immunologic response and side effects of using the WOKVAC vaccine in combination with chemotherapy and HER2-targeted monoclonal antibody therapy before surgery in treating patients with breast cancer. Vaccines like WOKVAC are made from tumor-associated antigens which may help the body build an effective immune response to kill tumor cells. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells,... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/25/2025

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8

Learn More ›

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738

Recruiting

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/25/2025

Locations: Research Site, Tucson, Arizona +290 locations

Research Site, Tucson, Arizona

Research Site, Springdale, Arkansas

Research Site, Beverly Hills, California

Research Site, Glendale, California

Research Site, Los Alamitos, California

Research Site, Redlands, California

Research Site, San Francisco, California

Research Site, Walnut Creek, California

Research Site, West Haven, Connecticut

Research Site, Newark, Delaware

Research Site, Bay Pines, Florida

Research Site, Fort Lauderdale, Florida

Research Site, Gainesville, Florida

Research Site, Jacksonville, Florida

Research Site, Athens, Georgia

Research Site, Atlanta, Georgia

Research Site, Boise, Idaho

Research Site, Chicago, Illinois

Research Site, Decatur, Illinois

Research Site, Hinsdale, Illinois

Research Site, Quincy, Illinois

Research Site, Waterloo, Iowa

Research Site, Lexington, Kentucky

Research Site, Louisville, Kentucky

Research Site, Alexandria, Louisiana

Research Site, Baton Rouge, Louisiana

Research Site, Covington, Louisiana

Research Site, Shreveport, Louisiana

Research Site, South Portland, Maine

Research Site, Baltimore, Maryland

Research Site, Bethesda, Maryland

Research Site, Detroit, Michigan

Research Site, Grand Rapids, Michigan

Research Site, Duluth, Minnesota

Research Site, Rochester, Minnesota

Research Site, Bridgeton, Missouri

Research Site, Columbia, Missouri

Research Site, Kansas City, Missouri

Research Site, Lincoln, Nebraska

Research Site, Camden, New Jersey

Research Site, Buffalo, New York

Research Site, East Syracuse, New York

Research Site, Westbury, New York

Research Site, Cincinnati, Ohio

Research Site, Bend, Oregon

Research Site, Medford, Oregon

Research Site, Salem, Oregon

Research Site, Hershey, Pennsylvania

Research Site, York, Pennsylvania

Research Site, Sioux Falls, South Dakota

Research Site, Chattanooga, Tennessee

Research Site, Nashville, Tennessee

Research Site, Fort Worth, Texas

Research Site, Houston, Texas

Research Site, Kingwood, Texas

Research Site, Lubbock, Texas

Research Site, Round Rock, Texas

Research Site, Fairfax, Virginia

Research Site, Fredericksburg, Virginia

Research Site, Olympia, Washington

Research Site, Seattle, Washington

Research Site, Silverdale, Washington

Research Site, Spokane, Washington

Research Site, Tacoma, Washington

Research Site, Wenatchee, Washington

Research Site, Buenos Aires, Not set

Research Site, Caba, Not set

Research Site, La Plata, Not set

Research Site, Pilar, Not set

Research Site, Rosario, Not set

Research Site, Darlinghurst, Not set

Research Site, Hyde Park, Not set

Research Site, Southport, Not set

Research Site, Wollongong, Not set

Research Site, Innsbruck, Not set

Research Site, Krems, Not set

Research Site, Rankweil, Not set

Research Site, Wien, Not set

Research Site, Anderlecht, Not set

Research Site, Brussels, Not set

Research Site, Charleroi, Not set

Research Site, Kortrijk, Not set

Research Site, Ottignies, Not set

Research Site, Sint-Niklaas, Not set

Research Site, Barretos, Not set

Research Site, Florianópolis, Not set

Research Site, Ijuí, Not set

Research Site, Londrina, Not set

Research Site, Porto Alegre, Not set

Research Site, Salvador, Not set

Research Site, Sao Paulo, Not set

Research Site, São Paulo, Not set

Research Site, Taubaté, Not set

Research Site, Saint John, New Brunswick

Research Site, Sydney, Nova Scotia

Research Site, Hamilton, Ontario

Research Site, Sault Ste. Marie, Ontario

Research Site, Montréal, Quebec

Research Site, Beijing, Not set

Research Site, Changchun, Not set

Research Site, Changde, Not set

Research Site, Changsha, Not set

Research Site, Chengdu, Not set

Research Site, Chongqing, Not set

Research Site, Dalian, Not set

Research Site, Guangzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Harbin, Not set

Research Site, Hefei, Not set

Research Site, Jinan, Not set

Research Site, Kunming, Not set

Research Site, Linhai, Not set

Research Site, Linyi, Not set

Research Site, Nanchang, Not set

Research Site, Ningbo, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Shenzhen, Not set

Research Site, Taiyuan, Not set

Research Site, Tianjin, Not set

Research Site, Wenzhou, Not set

Research Site, Wuhan, Not set

Research Site, Xi'an, Not set

Research Site, Yangzhou, Not set

Research Site, Yueyang, Not set

Research Site, Zhengzhou, Not set

Research Site, Avignon, Not set

Research Site, La Rochelle Cedex, Not set

Research Site, Lyon, Not set

Research Site, Nimes, Not set

Research Site, Rennes, Not set

Research Site, Strasbourg Cedex, Not set

Research Site, Suresnes, Not set

Research Site, Toulon Cedex 9, Not set

Research Site, Bad Berka, Not set

Research Site, Berlin, Not set

Research Site, Esslingen, Not set

Research Site, Frankfurt, Not set

Research Site, Gauting, Not set

Research Site, Gießen, Not set

Research Site, Großhansdorf, Not set

Research Site, Hamburg, Not set

Research Site, Hannover, Not set

Research Site, Heidelberg, Not set

Research Site, Hemer, Not set

Research Site, Homburg, Not set

Research Site, Kassel, Not set

Research Site, Kiel, Not set

Research Site, Krefeld, Not set

Research Site, Köln, Not set

Research Site, Minden, Not set

Research Site, Moers, Not set

Research Site, München, Not set

Research Site, Regensburg, Not set

Research Site, Würzburg, Not set

Research Site, Budapest, Not set

Research Site, Debrecen, Not set

Research Site, Gyöngyös, Not set

Research Site, Győr, Not set

Research Site, Pécs, Not set

Research Site, Székesfehérvár, Not set

Research Site, Törökbálint, Not set

Research Site, Calicut, Not set

Research Site, Delhi, Not set

Research Site, Kolkata, Not set

Research Site, Madurai, Not set

Research Site, Mumbai, Not set

Research Site, Nashik, Not set

Research Site, New Delhi, Not set

Research Site, Pondicherry, Not set

Research Site, Surat, Not set

Research Site, Varanasi, Not set

Research Site, Firenze, Not set

Research Site, Monza, Not set

Research Site, Orbassano, Not set

Research Site, Padova, Not set

Research Site, Peschiera Del Garda, Not set

Research Site, Roma, Not set

Research Site, Amagasaki-shi, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Chuo-ku, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Hiroshima-shi, Not set

Research Site, Kawagoe-shi, Not set

Research Site, Kitaadachi-gun, Not set

Research Site, Kitakyushu-shi, Not set

Research Site, Kobe-shi, Not set

Research Site, Koto-ku, Not set

Research Site, Kumamoto-shi, Not set

Research Site, Matsusaka-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Osakasayama, Not set

Research Site, Ota-shi, Not set

Research Site, Saitama-shi, Not set

Research Site, Sendai-shi, Not set

Research Site, Shinjuku-ku, Not set

Research Site, Yokohama-shi, Not set

Research Site, Cheongju-si, Not set

Research Site, Incheon, Not set

Research Site, Seoul, Not set

Research Site, Suwon-si, Not set

Research Site, George Town, Not set

Research Site, Johor Bahru, Not set

Research Site, Kuala Lumpur, Not set

Research Site, Alkmaar, Not set

Research Site, Ede, Not set

Research Site, Groningen, Not set

Research Site, Leidschendam, Not set

Research Site, Veldhoven, Not set

Research Site, Zwolle, Not set

Research Site, Lima, Not set

Research Site, Biała Podlaska, Not set

Research Site, Białystok, Not set

Research Site, Bydgoszcz, Not set

Research Site, Bystra, Not set

Research Site, Poznań, Not set

Research Site, Warszawa, Not set

Research Site, Łódź, Not set

Research Site, San Juan, Not set

Research Site, Barcelona, Not set

Research Site, Las Palmas de Gran Canaria, Not set

Research Site, Lérida, Not set

Research Site, Madrid, Not set

Research Site, Majadahonda, Not set

Research Site, Sevilla, Not set

Research Site, Kaohsiung, Not set

Research Site, New Taipei, Not set

Research Site, Taichung, Not set

Research Site, Tainan City, Not set

Research Site, Taoyuan, Not set

Research Site, Bangkok, Not set

Research Site, Chiang Mai, Not set

Research Site, Dusit, Not set

Research Site, Nakhon Ratchasima, Not set

Research Site, Songkla, Not set

Research Site, Antalya, Not set

Research Site, İstanbul, Not set

Research Site, Yenimahalle, Not set

Research Site, Aberdeen, Not set

Research Site, Cambridge, Not set

Research Site, Edinburgh, Not set

Research Site, Exeter, Not set

Research Site, Greater London, Not set

Research Site, London, Not set

Research Site, Manchester, Not set

Research Site, Newcastle upon Tyne, Not set

Research Site, Preston, Not set

Research Site, Can Tho, Not set

Research Site, Hanoi, Not set

Research Site, Ho Chi Minh City, Not set

Research Site, Ho Chi Minh, Not set

Research Site, Vinh, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

NCT04762953

Recruiting

This is a phase II clinical trial assessing the safety and efficacy of sequential systemic and intraperitoneal (IP) chemotherapy in patients with primary gastric/gastroesophageal junction cancer with cytology positive peritoneal lavage and/or peritoneal carcinomatosis.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

07/24/2025

Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

Conditions: Gastric Cancer, Peritoneal Carcinomatosis, Gastroesophageal Junction Adenocarcinoma

Learn More ›

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

NCT07096362

Not Yet Recruiting

The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study whether these levels of ctDNA can be used to make treatment decisions faster than the current standard approach, which is to wait 8 weeks after starting chemotherapy to obtain participant first imaging scans since starting chemotherapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: University of Miami, Miami, Florida

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma

Learn More ›

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868

Recruiting

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: Local Institution - 0303, Hot Springs, Arkansas +241 locations

Local Institution - 0303, Hot Springs, Arkansas

Local Institution - 0307, Cerritos, California

Local Institution - 0308, Cerritos, California

Local Institution - 0309, Cerritos, California

Local Institution - 0311, Long Beach, California

Local Institution - 0290, Los Angeles, California

Local Institution - 0283, Los Angeles, California

Local Institution - 0328, Whittier, California

Local Institution - 0289, Aurora, Colorado

Local Institution - 0304, Newark, Delaware

Local Institution - 0282, Miami, Florida

Local Institution - 0296, Pembroke Pines, Florida

Local Institution - 0294, Atlanta, Georgia

Local Institution - 0278, Chicago, Illinois

Local Institution - 0280, Chicago, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Local Institution - 0324, O'Fallon, Illinois

Local Institution - 0286, Covington, Louisiana

Local Institution - 0288, Boston, Massachusetts

Local Institution - 0287, Boston, Massachusetts

Local Institution - 0313, Minneapolis, Minnesota

Local Institution - 0284, Kansas City, Missouri

Local Institution - 0312, New York, New York

Local Institution - 0279, New York, New York

Clinical Research Alliance, Westbury, New York

Local Institution - 0285, White Plains, New York

Local Institution - 0276, Durham, North Carolina

Local Institution - 0316, Eugene, Oregon

Local Institution - 0310, Philadelphia, Pennsylvania

Local Institution - 0281, Greenville, South Carolina

Local Institution - 0315, Austin, Texas

Local Institution - 0314, Houston, Texas

Local Institution - 0305, Tyler, Texas

Local Institution - 0277, Midlothian, Virginia

Local Institution - 0301, Roanoke, Virginia

Local Institution - 0302, Winchester, Virginia

Local Institution - 0345, Buenas Aires, Buenos Aires

Local Institution - 0011, Ciudad autónoma de Buenos Aires, Buenos Aires

Local Institution - 0214, ABB, Ciudad Autónoma De Buenos Aires

Local Institution - 0143, Cordoba, Córdoba

Local Institution - 0137, Río Cuarto, Córdoba

Local Institution - 0142, Rosario, Santa Fe

Local Institution - 0317, Buenos Aires, Not set

Local Institution - 0346, Buenos Aires, Not set

Local Institution - 0012, Ciudad Autónoma de Buenos Aires, Not set

Local Institution - 0035, Brisbane, Queensland

Local Institution - 0197, Ballarat Central, Victoria

Local Institution - 0031, Heidelberg, Victoria

Local Institution - 0274, Melbourne, Victoria

Local Institution - 0028, Subiaco, Western Australia

Local Institution - 0292, Graz, Steiermark

Local Institution - 0268, Innsbruck, Tirol

Local Institution - 0267, Salzburg, Not set

Local Institution - 0270, St. Polten, Not set

Local Institution - 0269, Wien, Not set

Local Institution - 0187, Manaus, Amazonas

Local Institution - 0147, Fortaleza, Ceará

Local Institution - 0157, Vitória, Espírito Santo

Local Institution - 0199, Porto Alegre, Rio Grande Do Sul

Local Institution - 0164, São José do Rio Preto, São Paulo

Local Institution - 0153, Rio de Janeiro, Not set

Local Institution - 0144, São Paulo, Not set

Local Institution - 0149, São Paulo, Not set

Local Institution - 0218, Kelowna, British Columbia

Local Institution - 0217, Victoria, British Columbia

Local Institution - 0265, Ottawa, Ontario

Local Institution - 0215, Montréal, Quebec

Local Institution - 0219, Montréal, Quebec

Local Institution - 0350, Saint-Jerome, Quebec

Local Institution - 0216, Sherbrooke, Quebec

Local Institution - 0138, Santiago, Región Metropolitana De Santiago

Local Institution - 0021, Santiago, Región Metropolitana De Santiago

Local Institution - 0017, Santiago, Región Metropolitana De Santiago

Local Institution - 0018, Santiago, Región Metropolitana De Santiago

Local Institution - 0016, Viña del Mar, Valparaíso

Local Institution - 0195, Medellín, Antioquia

Local Institution - 0201, Rionegro, Antioquia

Local Institution - 0194, Barranquilla, Atlántico

Local Institution - 0182, Puerto Colombia, Atlántico

Local Institution - 0181, Montería, COR

Local Institution - 0327, Bogota, Cundinamarca

Local Institution - 0183, Cali, Valle Del Cauca

Local Institution - 0349, Medellin, Not set

Local Institution - 0089, Bordeaux, Aquitaine

Local Institution - 0272, Dijon, Côte-d'Or

Local Institution - 0098, Toulouse, Haute-Garonne

Local Institution - 0095, Montpellier, Hérault

Local Institution - 0099, Rennes, Ille-et-Vilaine

Local Institution - 0092, Saint Herblain, Loire-Atlantique

Local Institution - 0091, Reims, Marne

Local Institution - 0097, Villejuif, Paris

Local Institution - 0093, Marseille, Provence-Alpes-Côte-d'Azur

Local Institution - 0096, Clermont-Ferrand, Puy-de-Dôme

Local Institution - 0090, Lyon, Rhône-Alpes

Local Institution - 0094, Lille, Not set

Local Institution - 0088, Paris, Not set

Local Institution - 0320, Esslingen, Baden-Württemberg

Local Institution - 0256, Augsburg, Bayern

Local Institution - 0271, München, Bayern

Local Institution - 0306, Frankfurt, Hessen

Local Institution - 0333, Langen, Hessen

Local Institution - 0257, Hannover, Niedersachsen

Local Institution - 0293, Düsseldorf, Nordrhein-Westfalen

Local Institution - 0263, Essen, Nordrhein-Westfalen

Local Institution - 0254, Leipzig, Sachsen

Local Institution - 0255, Lübeck, Schleswig-Holstein

Local Institution - 0261, Berlin, Not set

Local Institution - 0260, Berlin, Not set

Local Institution - 0259, Bonn, Not set

Local Institution - 0258, Dresden, Not set

Local Institution - 0262, Heidelberg, Not set

Local Institution - 0291, Ulm, Not set

Local Institution - 0042, Athens, Attikí

Local Institution - 0038, Athens, Attikí

Local Institution - 0086, Heraklion, Irakleío

Local Institution - 0043, Athens, Not set

Local Institution - 0266, New Delhi, Delhi

Local Institution - 0206, New Delhi, Delhi

Local Institution - 0131, Mumbai, Maharashtra

Local Institution - 0134, Nagpur, Maharashtra

Local Institution - 0125, Chennai, Tamil Nadu

Local Institution - 0130, Hyderabad, Telangana

Local Institution - 0133, Varanasi, Uttar Pradesh

Local Institution - 0352, New Delhi, Not set

Local Institution - 0186, Petah Tikva, HaMerkaz

Local Institution - 0044, Ramat Gan, HaMerkaz

Local Institution - 0048, Hadera, HaTsafon

Local Institution - 0123, Haifa, HaTsafon

Local Institution - 0047, Jerusalem, Yerushalayim

Local Institution - 0051, Napoli, Campania

Local Institution - 0049, Bologna, Emilia-Romagna

Local Institution - 0057, Aviano, Friuli-Venezia Giulia

Local Institution - 0054, Genova, Liguria

Local Institution - 0053, Pontedera, Pisa

Local Institution - 0055, Prato, Toscana

Local Institution - 0052, Milano, Not set

Local Institution - 0058, Napoli, Not set

Local Institution - 0061, Novara, Not set

Local Institution - 0056, Padova, Not set

Local Institution - 0062, Roma, Not set

Local Institution - 0236, Nagoya, Aichi

Local Institution - 0230, Chiba-shi, Chiba

Local Institution - 0240, Matsuyama, Ehime

Local Institution - 0226, Otashi, Gunma

Local Institution - 0222, Sapporo, Hokkaido

Local Institution - 0232, Kanazawa, Ishikawa

Local Institution - 0234, Isehara, Kanagawa

Local Institution - 0237, Yokohama, Kanagawa

Local Institution - 0246, Tsu, Mie

Local Institution - 0223, Sendai-shi, Miyagi

Local Institution - 0238, Suita, Osaka

Local Institution - 0227, Hidaka, Saitama

Local Institution - 0224, Ina-machi, Saitama

Local Institution - 0231, Bunkyo-ku, Tokyo

Local Institution - 0229, Chuo-ku, Tokyo

Local Institution - 0228, Koto, Tokyo

Local Institution - 0245, Shinagawa, Tokyo

Local Institution - 0233, Shinjuku-ku, Tokyo

Local Institution - 0242, Fukuoka, Not set

Local Institution - 0225, Fukushima, Not set

Local Institution - 0243, Hiroshima, Not set

Local Institution - 0244, Kagoshima, Not set

Local Institution - 0235, Kyoto, Not set

Local Institution - 0241, Okayama, Not set

Local Institution - 0239, Osaka, Not set

Local Institution - 0066, Goyang-si, Kyǒnggi-do

Local Institution - 0067, Seongnam, Kyǒnggi-do

Local Institution - 0068, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0063, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0071, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0064, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0065, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0069, Daegu, Taegu-Kwangyǒkshi

Local Institution - 0264, Tijuana, Baja California

Local Institution - 0177, Mexico City, DIF

Local Institution - 0329, Mexico City, Distrito Federal

Local Institution - 0178, Guadalajara, Jalisco

Local Institution - 0175, Monterrey, Nuevo León

Local Institution - 0176, Monterrey, Nuevo León

Local Institution - 0173, Oaxaca de Juarez, Oaxaca

Local Institution - 0179, Merida, Yucatán

Local Institution - 0174, Chihuahua, Not set

Local Institution - 0074, Biala Podlaska, Lubelskie

Local Institution - 0072, Warszawa, Mazowieckie

Local Institution - 0220, Warszawa, Mazowieckie

Local Institution - 0076, Opole, Opolskie

Local Institution - 0189, Skórzewo, Wielkopolskie

Local Institution - 0221, Łódź, Łódzkie

Local Institution - 0198, Lisbon, Lisboa

Local Institution - 0106, Lisbon, Lisboa

Local Institution - 0109, Lisbon, Lisboa

Local Institution - 0124, Coimbra, Not set

Local Institution - 0141, Lisboa, Not set

Local Institution - 0111, Porto, Not set

Local Institution - 0253, Porto, Not set

Local Institution - 0212, Bistrita, Bistrița-Năsăud

Local Institution - 0213, Bucharest, București

Local Institution - 0079, Florești, Cluj

Local Institution - 0078, Craiova, Dolj

Local Institution - 0084, Ploiești, Prahova

Local Institution - 0211, Dumbravita, Timiș

Local Institution - 0085, Timișoara, Timiș

Local Institution - 0083, București, Not set

Local Institution - 0077, Cluj, Not set

Local Institution - 0081, Iași, Not set

Local Institution - 0080, Iași, Not set

Local Institution - 0351, East London, Eastern Cape

Local Institution - 0342, Parktown, Gauteng

Local Institution - 0336, Pretoria, Gauteng

Local Institution - 0341, Pretoria, Gauteng

Local Institution - 0340, Soweto, Gauteng

Local Institution - 0105, A Coruña, A Coruña [La Coruña]

Local Institution - 0100, Elche, Alicante

Local Institution - 0102, Barcelona, Barcelona [Barcelona]

Local Institution - 0172, Hospitalet, Barcelona [Barcelona]

Local Institution - 0140, Barcelona, Catalunya [Cataluña]

Local Institution - 0139, San Sebastian, Gipuzkoa

Local Institution - 0104, Madrid, Madrid, Comunidad De

Local Institution - 0108, Madrid, Madrid, Comunidad De

Local Institution - 0101, Malaga, Málaga

Local Institution - 0210, Valencia, Valenciana, Comunitat

Local Institution - 0107, Madrid, Not set

Local Institution - 0103, Sevilla, Not set

Local Institution - 0252, Malmö, Skåne Län [se-12]

Local Institution - 0026, Stockholm, Stockholms Län [se-01]

Local Institution - 0025, Uppsala, Uppsala Län [se-03]

Local Institution - 0024, Örebro, Örebro Län [se-18]

Local Institution - 0247, Linköping, Östergötlands Län [se-05]

Local Institution - 0250, st.Gallen, Sankt Gallen

Local Institution - 0249, Lausanne, Vaud

Local Institution - 0251, Zürich, Not set

Local Institution - 0323, Abu Dhabi, Abū Z̧aby

Local Institution - 0318, Abu Dhabi, Abū Z̧aby

Local Institution - 0322, Al Ain, Abū Z̧aby

Local Institution - 0319, Abu Dhabi, Not set

Local Institution - 0208, Truro, England

Local Institution - 0204, London, London, City Of

Local Institution - 0209, London, London, City Of

Local Institution - 0171, Belfast, Not set

Local Institution - 0004, London, Not set

Local Institution - 0001, Manchester, Not set

Local Institution - 0006, Nottingham, Not set

Conditions: Breast Neoplasms

Learn More ›

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

NCT04428151

Active Not Recruiting

Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic). Some people with recurrent or metastatic head and neck cancer are treated with chemotherapy and immunotherapy, but the cancer gets worse. The goal of this study is to learn if more people who receive lenvatinib and pembrolizumab have a better overall survival rate than people who receive standard... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: City of Hope ( Site 1519), Duarte, California +119 locations

City of Hope ( Site 1519), Duarte, California

UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1568), Los Angeles, California

Yale-New Haven Hospital-Yale Cancer Center ( Site 1505), New Haven, Connecticut

Georgetown University Medical Center ( Site 1520), Washington, District of Columbia

UF Health ( Site 1554), Gainesville, Florida

Mid Florida Hematology and Oncology Center ( Site 1606), Orange City, Florida

Cleveland Clinic Florida ( Site 1596), Weston, Florida

Georgia Cancer Center at Augusta University ( Site 1575), Augusta, Georgia

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1521), Marietta, Georgia

Memorial Health University Medical Center ( Site 1626), Savannah, Georgia

Beacon Cancer Care ( Site 1599), Post Falls, Idaho

Rush University Medical Center ( Site 1560), Chicago, Illinois

NorthShore University HealthSystem - Evanston Hospital ( Site 1614), Evanston, Illinois

IU Health Ball Memorial Hospital, Inc.-IU Health Ball Memorial Cancer Center ( Site 1612), Muncie, Indiana

University of Iowa ( Site 1572), Iowa City, Iowa

University of Kansas Cancer Center ( Site 1538), Westwood, Kansas

Norton Hospital-Norton Cancer Institute - Downtown ( Site 1601), Louisville, Kentucky

Mercy Health-Paducah Cancer Center ( Site 1623), Paducah, Kentucky

Our Lady of the Lake RMC-Clinical Research ( Site 1624), Baton Rouge, Louisiana

Mary Bird Perkins Cancer Center Baton Rouge ( Site 1622), Baton Rouge, Louisiana

University of Maryland Greenebaum Cancer Center ( Site 1522), Baltimore, Maryland

Boston Medical Center ( Site 1605), Boston, Massachusetts

University of Massachusetts Chan Medical School ( Site 1616), Worcester, Massachusetts

VA Ann Arbor Healthcare System ( Site 1584), Ann Arbor, Michigan

Barbara Ann Karmanos Cancer Institute ( Site 1566), Detroit, Michigan

Henry Ford Health System ( Site 1544), Detroit, Michigan

Hattiesburg Clinic ( Site 1515), Hattiesburg, Mississippi

Jackson Oncology Associates, PLLC-Clinical Trials ( Site 1625), Jackson, Mississippi

Washington University School of Medicine ( Site 1500), Saint Louis, Missouri

St. Vincent Frontier Cancer Center ( Site 1507), Billings, Montana

University Of Nebraska Medical Center ( Site 1570), Omaha, Nebraska

Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 1627), Omaha, Nebraska

John Theurer Cancer Center at Hackensack University Medical Center ( Site 1555), Hackensack, New Jersey

Rutgers Cancer Institute of New Jersey ( Site 1523), New Brunswick, New Jersey

Perlmutter Cancer Center at Winthrop Oncology Hematology Associates NYU Langone Health ( Site 1597), Mineola, New York

Laura and Isaac Perlmutter Cancer Center ( Site 1582), New York, New York

Levine Cancer Institute ( Site 1590), Charlotte, North Carolina

Duke Cancer Institute ( Site 1541), Durham, North Carolina

University of Cincinnati Medical Center ( Site 1567), Cincinnati, Ohio

University Hospital Cleveland ( Site 1578), Cleveland, Ohio

Cleveland Clinic Main ( Site 1598), Cleveland, Ohio

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 1558), Columbus, Ohio

Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1508), Tulsa, Oklahoma

Gettysburg Cancer Center ( Site 1594), Gettysburg, Pennsylvania

Penn State Hershey Medical Center ( Site 1561), Hershey, Pennsylvania

Fox Chase Cancer Center ( Site 1502), Philadelphia, Pennsylvania

Medical University of South Carolina ( Site 1579), Charleston, South Carolina

St Francis Cancer Center-Research Office ( Site 1607), Greenville, South Carolina

The Center For Cancer And Blood Disorders ( Site 1569), Fort Worth, Texas

Utah Cancer Specialists ( Site 1621), Salt Lake City, Utah

Huntsman Cancer Institute ( Site 1532), Salt Lake City, Utah

Inova Schar Cancer Institute ( Site 1550), Fairfax, Virginia

Hematology Oncology Associates of Fredericksburg ( Site 1537), Fredericksburg, Virginia

MultiCare Health System-MultiCare Oncology - Puget Sound ( Site 1609), Tacoma, Washington

Medical College of Wisconsin Clinical Cancer Center ( Site 1574), Milwaukee, Wisconsin

Mid North Coast Cancer Institute ( Site 0109), Port Macquarie, New South Wales

Blacktown Hospital ( Site 0101), Sydney, New South Wales

The Townsville Hospital ( Site 0107), Douglas, Queensland

Gallipoli Medical Research Ltd-GMRF CTU ( Site 0105), Greenslopes, Queensland

Royal Adelaide Hospital ( Site 0110), Adelaide, South Australia

Monash Health ( Site 0102), Clayton, Victoria

Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0806), Porto Alegre, Rio Grande Do Sul

A. C. Camargo Cancer Center ( Site 0809), Sao Paulo, Not set

Arthur J.E. Child Comprehensive Cancer Centre ( Site 0304), Calgary, Alberta

BC Cancer-Vancouver Center ( Site 0306), Vancouver, British Columbia

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0307), Hamilton, Ontario

Sunnybrook Research Institute ( Site 0308), Toronto, Ontario

Instituto de Cancerología ( Site 0408), Medellin., Antioquia

Sociedad De Oncologia Y Hematologia Del Cesar ( Site 0404), Valledupar, Cesar

IMAT S.A.S ( Site 0409), Montería, Cordoba

Administradora Country S.A.S - Clínica del Country ( Site 0407), Bogotá, Cundinamarca

Rigshospitalet University Hospital Copenhagen ( Site 1000), Copenhagen, Hovedstaden

Hopital La Timone ( Site 0503), Marseille, Bouches-du-Rhone

Centre de Cancerologie du Grand Montpellier ( Site 0508), Montpellier, Herault

Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 0510), Clermont-Ferrand, Puy-de-Dome

Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen ( Site 0509), Rouen, Seine-Maritime

Institut Gustave Roussy ( Site 0505), Villejuif, Val-de-Marne

Institut Curie ( Site 0500), Paris, Not set

Soroka Medical Center-Oncology ( Site 0604), Be'er Sheva, Not set

Rambam Health Care Campus-Oncology Division ( Site 0602), Haifa, Not set

Hadassah Medical Center. Ein Kerem ( Site 0601), Jerusalem, Not set

Chaim Sheba Medical Center ( Site 0600), Ramat Gan, Not set

Seoul National University Bundang Hospital ( Site 1801), Seongnam, Kyonggi-do

Ajou University Hospital ( Site 1802), Suwon, Kyonggi-do

Severance Hospital Yonsei University Health System ( Site 1800), Seoul, Not set

Samsung Medical Center ( Site 1803), Seoul, Not set

Oslo universitetssykehus, Radiumhospitalet ( Site 1102), Oslo, Not set

Unidade Local de Saude Gaia/Espinho - Hospital Eduardo Santos Silva ( Site 1401), Vila Nova de Gaia, Porto

Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 1400), Porto, Not set

MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 1703), Bucharest, Bucuresti

Spitalul Clinic Colțea ( Site 1708), București, Bucuresti

Cardiomed SRL Cluj-Napoca ( Site 1701), Cluj Napoca, Cluj

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1702), Cluj Napoca, Cluj

S.C. Radiotherapy Center Cluj S.R.L ( Site 1706), Floresti, Cluj

S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1704), Craiova, Dolj

Cabinet Medical Oncomed ( Site 1707), Timisoara, Timis

Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0700), Hospitalet de Llobregat, Barcelona

HOSPITAL CLÍNIC DE BARCELONA ( Site 0707), Barcelona, Cataluna

Centro Oncologico de Galicia ( Site 0706), A Coruna, Galicia

Hospital General de Valencia ( Site 0703), Valencia, Valenciana, Comunitat

Hospital Universitari Vall d Hebron ( Site 0701), Barcelona, Not set

Hospital Ramon y Cajal ( Site 0705), Madrid, Not set

Hospital Virgen de la Victoria ( Site 0702), Malaga, Not set

Chang Gung Medical Foundation - Kaohsiung ( Site 1204), Kaohsiung, Not set

China Medical University Hospital ( Site 1205), Taichung, Not set

Taichung Veterans General Hospital ( Site 1206), Taichung, Not set

National Cheng Kung University Hospital ( Site 1202), Tainan, Not set

National Taiwan University Hospital ( Site 1200), Taipei, Not set

Taipei Veterans General Hospital ( Site 1201), Taipei, Not set

Chang Gung Memorial Hospital - Linkou Branch ( Site 1203), Taoyuan, Not set

Aberdeen Royal Infirmary ( Site 0911), Aberdeen, Aberdeen City

Castle Hill Hospital ( Site 0910), Cottingham, East Riding Of Yorkshire

The Beatson West of Scotland Cancer Centre ( Site 0909), Glasgow, Glasgow City

Guy s and St Thomas Hospital NHS Foundation Trust ( Site 0903), London, Great Britain

University Hospital Southampton NHS Foundation Trust ( Site 0905), Southampton, Hampshire

Royal Marsden Hospital ( Site 0902), London, London, City Of

Charing Cross Hospital ( Site 0908), London, London, City Of

Musgrove Park Hospital ( Site 0904), Taunton, Somerset

Royal Marsden Hospital. ( Site 0901), Sutton, Surrey

The Christie NHS Foundation Trust ( Site 0907), Manchester, Not set

Conditions: Squamous Cell Carcinoma of Head and Neck

Learn More ›

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665

Recruiting

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) wh... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: Pioneer Research Center, LLC, Bullhead City, Arizona +11 locations

Conditions: Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent

Learn More ›

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

NCT05422794

Recruiting

This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the body (advanced). Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanopar... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: Boston Medical Center, Boston, Massachusetts +4 locations

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma

Learn More ›

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

NCT04251533

Active Not Recruiting

The purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA mutation (Study Part B2)

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

07/23/2025

Locations: University of California LA, Los Angeles, California +77 locations

University of California LA, Los Angeles, California

Hematology and Oncology Clinic, Baton Rouge, Louisiana

Mayo Clinic Rochester, Rochester, Minnesota

Park Nicollet Institute, Saint Louis Park, Minnesota

SCRI Oncology Partners, Nashville, Tennessee

Novartis Investigative Site, Caba, Buenos Aires

Novartis Investigative Site, Rosario, Santa Fe

Novartis Investigative Site, Melbourne, Victoria

Novartis Investigative Site, Nedlands, Western Australia

Novartis Investigative Site, Innsbruck, Tyrol

Novartis Investigative Site, Leoben, Not set

Novartis Investigative Site, Barretos, SP

Novartis Investigative Site, Sao Paulo, SP

Novartis Investigative Site, Plovdiv, Not set

Novartis Investigative Site, Hefei, Anhui

Novartis Investigative Site, Shijiazhuang, Hebei

Novartis Investigative Site, Changsha, Hunan

Novartis Investigative Site, Nanjing, Jiangsu

Novartis Investigative Site, Nanchang, Jiangxi

Novartis Investigative Site, Chang Chun, Jilin

Novartis Investigative Site, Shengyang, Liaoning

Novartis Investigative Site, Shenyang, Liaoning

Novartis Investigative Site, Chengdu, Sichuan

Novartis Investigative Site, Hangzhou, Zhejiang

Novartis Investigative Site, Dalian, Not set

Novartis Investigative Site, Shanghai, Not set

Novartis Investigative Site, Tianjin, Not set

Novartis Investigative Site, Bogota, Not set

Novartis Investigative Site, Zagreb, Not set

Novartis Investigative Site, Saint-Cloud, Hauts De Seine

Novartis Investigative Site, Angers 02, Not set

Novartis Investigative Site, Saint Herblain, Not set

Novartis Investigative Site, Villejuif, Not set

Novartis Investigative Site, Leipzig, Sachsen

Novartis Investigative Site, Dresden, Not set

Novartis Investigative Site, Essen, Not set

Novartis Investigative Site, Budapest, Not set

Novartis Investigative Site, Faridabad, Haryana

Novartis Investigative Site, Mumbai, Maharashtra

Novartis Investigative Site, Vellore, Tamil Nadu

Novartis Investigative Site, Hyderabad, Telangana

Novartis Investigative Site, Tel Aviv, Not set

Novartis Investigative Site, Meldola, FC

Novartis Investigative Site, Roma, RM

Novartis Investigative Site, Napoli, Not set

Novartis Investigative Site, Seoul, Not set

Novartis Investigative Site, Petaling Jaya, Selangor

Novartis Investigative Site, Kuala Lumpur, Not set

Novartis Investigative Site, Monterrey, Nuevo Leon

Novartis Investigative Site, Oslo, Not set

Novartis Investigative Site, Trujillo, La Libertad

Novartis Investigative Site, Gdynia, Not set

Novartis Investigative Site, Opole, Not set

Novartis Investigative Site, Poznan, Not set

Novartis Investigative Site, Arkhangelsk, Not set

Novartis Investigative Site, Chelyabinsk, Not set

Novartis Investigative Site, Moscow, Not set

Novartis Investigative Site, Pushkin Saint Petersburg, Not set

Novartis Investigative Site, Bratislava, Slovak Republic

Novartis Investigative Site, Bratislava, Not set

Novartis Investigative Site, Kosice, Not set

Novartis Investigative Site, Ljubljana, Not set

Novartis Investigative Site, Port Elizabeth, Western Cape

Novartis Investigative Site, Johannesburg, Not set

Novartis Investigative Site, Badajoz, Extremadura

Novartis Investigative Site, Palma De Mallorca, Islas Baleares

Novartis Investigative Site, Alicante, Not set

Novartis Investigative Site, Lausanne, Not set

Novartis Investigative Site, Taipei, Not set

Novartis Investigative Site, Istanbul, Not set

Novartis Investigative Site, Nottingham, Not set

Novartis Investigative Site, Oxford, Not set

Conditions: Triple Negative Breast Neoplasms

Learn More ›

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

NCT03564691

Active Not Recruiting

This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Arms A and B) and in combination with pembrolizumab (Arm C). Dose expansion is to evaluate the objective response rate (ORR) of MK-4830 in combination with pembrolizumab (Arms A-F); evaluate the safety and tolerability of MK-4830 a... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: University of California at San Francisco ( Site 0004), San Francisco, California +36 locations

University of California at San Francisco ( Site 0004), San Francisco, California

Henry Ford Health System ( Site 0002), Detroit, Michigan

Washington University ( Site 0003), Saint Louis, Missouri

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005), Hackensack, New Jersey

Laura and Isaac Perlmutter Cancer Center ( Site 0008), New York, New York

Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 00, Columbus, Ohio

South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001), San Antonio, Texas

Utah Cancer Specialists ( Site 0011), Salt Lake City, Utah

Seattle Cancer Care Alliance ( Site 0010), Seattle, Washington

Liverpool Hospital-Medical Oncology ( Site 0250), Liverpool, New South Wales

Princess Alexandra Hospital ( Site 0253), Brisbane, Queensland

Juravinski Cancer Centre ( Site 0034), Hamilton, Ontario

The Ottawa Hospital ( Site 0031), Ottawa, Ontario

Princess Margaret Cancer Centre ( Site 0033), Toronto, Ontario

The First Hospital of Jilin University ( Site 0803), Changchun, Jilin

Shanghai Chest Hospital-Oncology department ( Site 0801), Shanghai, Shanghai

West China Hospital of Sichuan University ( Site 0804), Chengdu, Sichuan

Hôpital Européen Georges Pompidou ( Site 2003), Paris, Ile-de-France

Centre Oscar Lambret ( Site 2002), Lille, Nord

Centre Hospitalier Universitaire de Poitiers ( Site 2000), Poitiers, Vienne

University General Hospital of Heraklion ( Site 0110), Heraklion, Irakleio

Euromedica General Clinic of Thessaloniki-Oncology Unit ( Site 0112), Thessaloniki, Not set

European Interbalkan Medical Center ( Site 0111), Thessaloniki, Not set

Rambam Health Care Campus-Oncology Division ( Site 0042), Haifa, Not set

Rabin Medical Center ( Site 0043), Petah Tikva, Not set

Chaim Sheba Medical Center. ( Site 0044), Ramat Gan, Not set

Sourasky Medical Center ( Site 0041), Tel Aviv, Not set

National Cancer Center Hospital East ( Site 0400), Kashiwa, Chiba

Japanese Foundation for Cancer Research ( Site 0401), Tokyo, Not set

Severance Hospital Yonsei University Health System ( Site 0300), Seoul, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie

Uniwersyteckie Centrum Kliniczne ( Site 0151), Gdansk, Pomorskie

Wits Clinical Research ( Site 0213), Johannesburg, Gauteng

The Oncology Centre ( Site 0212), Durban, Kwazulu-Natal

Cancercare Rondebosch Oncology ( Site 0210), Cape Town, Western Cape

Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0101), Hospitalet de Llobregat, Barcelona

Centro Integral Oncologico Clara Campal START Madrid ( Site 0102), Madrid, Not set

Conditions: Neoplasms

Learn More ›

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

NCT01506973

Completed

In this Phase I/II clinical trial, the investigators seek to pilot the addition of Hydroxychloroquine (HCQ) to a commonly-used front-line therapy of pancreatic cancer, gemcitabine/nab-paclitaxel. The investigators plan a run-in to define tolerable doses, and will explore doses of 800 and 1200 mg/day in successive cohorts of 6 patients. The investigators will assess toxicity continuously, and determine the dose for the Phase II trial based on standard toxicity criteria. The correlative endpoints of this trial are directed to the pharmacokinetics of HCQ, and pharmacokinetic model of HCQ based on data from several ongoing trials, and the data from these patients will contribute to refining the model. The investigators will analyze both measured and model-predicted indices for their relationship to autophagy induction. Autophagy will be assessed as the accumulation of autophagocytic vesicles in the PMNs of treated patients, together with the induction of the expression of autophagy-related proteins on western analysis, quantitated by densitometry. The investigators will document the rates of metabolic response as a consequence of treatment, as a therapeutic marker that may be related to the degree of autophagy inhibition. Since the investigators have previously demonstrated a key role of JNK1 in the induction of autophagy by chemotherapy, the investigators will analyze archival tumor materials to determine variability in this marker, as a baseline for potential future trials. Finally, this study will incorporate metabolic profiling by mass spectrometry, which will be related to mutations (including Kras) in pretreatment tumor specimens. Mutational analysis will be accomplished by targeted sequencing or by next-generation sequencing, and the need for fresh tissue for all these endpoints will require patients to have a biopsy performed before treatment at at 6-8 weeks after beginning treatment. In the previous study of the Hh inhibitor GDC-0973 with the same chemotherapy, the investigators were able to obtain repeat biopsies successfully on all patients. The importance of these biopsies, to move the science forward in an era in which the tools now exist to provide meaningful correlative science, cannot be overstated. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/22/2025

Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

Conditions: Advanced Adenocarcinoma, Metastatic Adenocarcinoma

Learn More ›

Browse by State

Paclitaxel treatment options in Alabama

Paclitaxel treatment options in Alaska

Paclitaxel treatment options in Arizona

Paclitaxel treatment options in Arkansas

Paclitaxel treatment options in California

Paclitaxel treatment options in Colorado

Paclitaxel treatment options in Connecticut

Paclitaxel treatment options in Delaware

Paclitaxel treatment options in District of Columbia

Paclitaxel treatment options in Florida

Paclitaxel treatment options in Georgia

Paclitaxel treatment options in Hawaii

Paclitaxel treatment options in Idaho

Paclitaxel treatment options in Illinois

Paclitaxel treatment options in Indiana

Paclitaxel treatment options in Iowa

Paclitaxel treatment options in Kansas

Paclitaxel treatment options in Kentucky

Paclitaxel treatment options in Louisiana

Paclitaxel treatment options in Maine

Paclitaxel treatment options in Montana

Paclitaxel treatment options in Nebraska

Paclitaxel treatment options in Nevada

Paclitaxel treatment options in New Hampshire

Paclitaxel treatment options in New Jersey

Paclitaxel treatment options in New Mexico

Paclitaxel treatment options in New York

Paclitaxel treatment options in North Carolina

Paclitaxel treatment options in North Dakota

Paclitaxel treatment options in Ohio

Paclitaxel treatment options in Oklahoma

Paclitaxel treatment options in Oregon

Paclitaxel treatment options in Maryland

Paclitaxel treatment options in Massachusetts

Paclitaxel treatment options in Michigan

Paclitaxel treatment options in Minnesota

Paclitaxel treatment options in Mississippi

Paclitaxel treatment options in Missouri

Paclitaxel treatment options in Pennsylvania

Paclitaxel treatment options in Rhode Island

Paclitaxel treatment options in South Carolina

Paclitaxel treatment options in South Dakota

Paclitaxel treatment options in Tennessee

Paclitaxel treatment options in Texas

Paclitaxel treatment options in Utah

Paclitaxel treatment options in Vermont

Paclitaxel treatment options in Virginia

Paclitaxel treatment options in Washington

Paclitaxel treatment options in West Virginia

Paclitaxel treatment options in Wisconsin

Paclitaxel treatment options in Wyoming